ALEXANDRIA, Va., Feb. 24 -- United States Patent no. 12,559,566, issued on Feb. 24, was assigned to DEBIOPHARM INTERNATIONAL S.A. (Lausanne, Switzerland).
"CD37-binding molecules immunoconjugates thereof" was invented by Jutta Deckert (Lexington, Mass.), Peter Park (Somerville, Mass.), Daniel Tavares (Natick, Mass.) and Lingyun Rui (Weston, Mass.).
According to the abstract* released by the U.S. Patent & Trademark Office: "Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided."
The patent was filed on Oct. 7, 2022, under Application No. 17/938,886...